Background: Angiogenesis is regulated by a balance of pro-angiogenic and anti-angiogenic factors. Vascular endothelial growth factor (VEGF) and endostatin respectively represents a frequent component of inducers and inhibitors in the process of angiogenesis. The ratio of VEGF/endostatin may reflect the balance of angiogenic switch. This study aimed to determine whether an imbalance between VEGF/ endostatin exists in operable non-small cell lung cancer (NSCLC) patients and to assess the correlation, if any, between the imbalance and the prognosis. Methods: Preoperative serum levels of VEGF and endostatin were simultaneously determined by quantitiative enzyme-linked immunosorbent assay (ELISA) and the ratio of them was calculated among 98 NSCLC patients and 51 healthy controls. The relationship between these factors and clinicopathological features, including prognosis, was examined. Results: The ratio of VEGF/endostatin levels was significantly higher in operable NSCLC patients [median, 10.4; interquartile range (IQR), 5.9e19.8] than in normal controls [median, 5
Introduction
Lung cancer is the most common cause of death from cancer worldwide, estimated to be responsible for 19 .4% (1.59 million) of all cancer deaths in 2012. 1 Despite diagnostic and therapeutic advances, the survival rate of lung cancer patients is still low (10% after 5 years), and has not changed over the period analyzed in the EUROCARE-4 study. 2 Non-small cell lung cancer (NSCLC) is the most common histological type of lung cancer, accounting for approximately 80% of lung cancers. 3 In the 1970s, Folkman postulated that tumor growth and metastasis are dependent on angiogenesis. 4 And now the importance of angiogenesis for the development of solid tumors is well recognized. It is acknowledged that angiogenesis is regulated by both promoters and inhibitors. When the stimulators accumulate in excess of inhibitors within an angiogenic tumor, the balance between the inducers and inhibitors is interrupted 5 and the "angiogenic switch" would be activated which progressively enhance the intensity of angiogenesis. 6 A variety pro-angiogenic factors have been described including vascular endothelial growth factor (VEGF). 7 An increasing number of anti-angiogenic factors such as endostatin and angiostatin also have been identified. 8 VEGF and endostatin are two factors which have been reported in more detail about their roles in the angiogenesis. VEGF, which is also known as vascular permeability factor (VPF), is the most powerful angiogenic factor known to date with direct effects on endothelial cell proliferation, migration and tubule formation under physiologic and pathologic conditions. 9 It acts through binding to VEGF receptor (VEGFR) generating a cascade of intracellular signaling, leading to activation of transcription factors in the nucleus that ultimately lead to new vessel formation. 10 Endostatin, a strong endogenous inhibitor of angiogenesis which was discovered as a 20 kDa internal fragment of the carboxy terminus of collagen XVIII, was reported to be identified in a matrix protein in 1994, 11 and was proved to be an endogenous angiogenesis inhibitor and a tumor suppressor in 2005. 12 Endostatin which is the most rigorously studied one of the endogenous angiogenesis inhibitors inhibits endothelial cell proliferation, migration/invasion, tubule formation and increases apoptosis of malignant cells. 13 Our overall hypothesis was that there is an imbalance of angiogenic factors in NSCLC patients since the balance of the inhibitors and inducers controls the angiogenic switch. Although there are many promoters and inhibitors involved in NSCLC angiogenesis, VEGF and endostatin might preliminarily represent the two categories respectively. This is a retrospective cohort study designed to determine whether an imbalance between VEGF and endostatin exists in operable NSCLC patients and evaluate the possible prognostic correlation of such imbalance.
Patients and methods

Subjects
Ninety-eight cases with NSCLC were enrolled in this study. Surgeries for radical resection of the tumors were performed consecutively for each of the patients in the Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, between February 2007 and July 2008. Inclusion criteria consisted of histologically or cytologically proven NSCLC and all patients were previously untreated with chemotherapy or radiotherapy. The pathological surgical staging IaeIIIa was done according to the 7th edition TNM staging classification in lung cancer. Simultaneously, 51 healthy volunteers were enrolled as the control group, brief history and physical examinations including the routine blood tests, electrocardiogram (ECG), chest X-ray, abdominal and pelvic ultrasound, etc. confirmed that they were healthy. This study was approved by the ethic committee of the Beijing Chest Hospital. Informed consent was obtained from each patient and healthy control.
Serum collection and measurements
Five milliliters of peripheral venous blood was obtained before surgery, then centrifuged at 1000 g for 15 min in a refrigerated centrifuge to get serum aliquots and stored at À80 C until further assay. The blood samples from control subjects were processed similarly. Blood samples were taken from the female subjects during non-menstrual period. The concentration of VEGF and endostatin in serum preoperatively were determined by a quantitative sandwich enzyme-linked immunosorbent assay (ELISA). The levels of serum VEGF and endostatin were determined according to the manufacturer's instructions of VEGF ELISA kit (Jingmei Biotech Co., Ltd, Beijing, China) and endostatin ELISA kit (R&D Systems, Minneapolis, MN, USA). All determinations were made in duplicate.
Statistical analysis
Statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). All data were expressed as medians, with the 25th percentile and 75th percentile, due to skewed distribution examined by KolmogoroveSmirnov test. Nonparametric statistical analyses were performed using ManneWhitney U test determining the differences between two independent groups and KruskaleWallis test for determining the differences among more than two groups.
Survival time was defined from the date of surgery to death or the date of the last follow-up. None of the patients died within 60 days after operation. Among the 98 patients, 1 patient could not be contacted soon after surgery and 2 patients were lost to follow-up in the third year after the operation. The median follow-up time was 55.7 months (range, 3.2e80.1 months).
The impact of the ratio VEGF/endostatin on survival in the subgroup analysis was assessed with the KaplaneMeier method and compared by the log rank test. To assess the independent value of different variables on survival, multivariate analysis was performed using the Cox proportional hazards model. Variables with p value <0.05 in univariate analysis were entered into the Cox regression analysis. In the study, P < 0.05 was considered statistically significant.
Results
Clinicopathological characteristics
The median age of the patients was 62 years (range, 36e84 years), 82.7% were males. The majority (53.1%) of tumors were squamous cell carcinoma. Among these 98 patients, pathological tumor stage included 43 (43.9%) cases at stage I, 22 (22.4%) at stage II, and 33 (33.7%) at stage III. The most frequently seen histological grade was moderately differentiated (83.7%) type of the tumor. Of the total cases, 74 (75.5%) underwent lobectomy, while 20 (20.4%) and 4 (4.1%) received pneumonectomy and sublobectomy (wedge resection or segmentectomy), respectively. In the control group, the median age was 60.5 years (range, 55e64 years), 72.5% of them were male. There were no significant differences in age and gender between the two groups ( Table 1) .
Circulating VEGF level, endostatin concentration and the ratio of VEGF/endostatin
The concentration of serum VEGF was significantly higher in operable NSCLC patients [median, 802.5 pg/mL (IQR, 501.4e1136.4 pg/mL)] than in healthy controls [median, 367.3 pg/mL (IQR, 209.9e557.7 pg/mL)] (P < 0.0001) (Fig. 1A) . Similarly, serum level of endostatin in lung cancer patients [median, 69.0 ng/mL (IQR, 53.3e85.8 ng/mL)] was significantly higher than that of the control volunteers [median 52.1 ng/mL (IQR, 45.5e83.1 ng/mL)] (P ¼ 0.016) (Fig. 1B) (Fig. 1C) .
Clinicopathological characteristics and VEGF/ endostatin level
The correlation between clinicopathological characteristics and serum level of VEGF, endostatin and the VEGF/endostatin ratio was summarized (Table 2) 
Survival analysis
The survival analysis of the 95 patients who could be followed up to the end of the study revealed that 46 of them (48.4%) were still alive with the median follow-up time: 74.1 months (range, 62.1e80.1 months). The median survival time among the patients who died was 16.7 months (range, 3.2e57.2 months). The survival time of the survivors was significantly longer than that of the nonsurvivors ( p < 0.0001).
The serum level of VEGF in the patients still alive was significantly lower than that in those who died [median, 687.0 pg/mL (IQR, 381.5e932.05 pg/mL) vs. 879.1 pg/ mL (IQR, 529.7e1254.6 pg/mL), respectively] ( p ¼ 0.049) (Fig. 2A) . The median level of the VEGF/endostatin ratio of the two groups were 8.3 (IQR, 4.3e17.9) vs. 12.9 (IQR, 8.0e22.1) respectively, the difference was also significant ( p ¼ 0.017) (Fig. 2B) . The median serum levels of endostatin were 68.5 ng/mL (IQR, 53.4e97.5 ng/mL) and 69.8 ng/mL (IQR, 52.1e80.5 ng/ mL) respectively, no significant difference was found between them ( p ¼ 0.396) (Fig. 2C) .
The analysis of the impact of VEGF/endostatin ratio on the survival in the subgroup of patients with pathological stage N0 showed that, there was a significant increase of the survival time in the group with lower ratio than in the group with higher ratio ( p ¼ 0.032) (median, 63.53, 55.67 months, respectively) (Fig. 3) .
The prognostic variables were determined by Cox proportional hazard regression analysis. In the univariate analysis, postsurgical TNM stage ( p < 0.0001), ratio of VEGF/ endostatin ( p ¼ 0.018) and the type of resection ( p ¼ 0.002) were significantly associated with survival time. The variables with P <0.05 were entered into the multivariate analysis and the result showed that postsurgical stage (P < 0.0001), ratio of VEGF/endostatin (P ¼ 0.045) and the type of resection (P ¼ 0.001) were the independent variables correlated with the prognosis of operable NSCLC (Table 3) . 
Discussion
The aim of this study was to analyze whether there was an imbalance of the angiogenic inducer and inhibitor in patients with operable NSCLC, and to study the correlation between the imbalance and the prognosis.
We hypothesized that there might be an imbalance between VEGF and endostatin, which represent the important component of the inducers and inhibitors involved in the angiogenesis. In this study, preoperative serum levels of VEGF and endostatin were examined and compared to 51 healthy controls by ELISA. The serum levels of VEGF and endostatin in operable NSCLC patients were significantly higher than those in control individuals. The result was consistent with the reports of other studies. 14e17 It is very interesting that both angiogenic activators and inhibitors are increased. We determined the ratio of VEGF/ endostatin and compared it with the ratio of the healthy control. The ratio was significantly increased in patients with operable NSCLC. A net balance of angiogenic inhibitors over activators would maintain the angiogenic switch in the off position, whereas a shift to an excess of activating stimuli would turn on angiogensis. 18 So we presumed that in the process of the angiogenesis, while the positive angiogenic factors including VEGF were induced to produce more, the negative angiogenic factors including endostatin also increased as a feedback to regulate the angiogenesis balance. But the increase of endostatin may be not proportionate to the increased level of VEGF, the balance would be changed. Then changes in the balance mediate the angiogenic switch which would benefit the progress of the cancer. 19 Although it was reported that VEGF was related to endostatin, 20 this study did not find significant correlation between them and it is in accordance with the result that VEGF and endostatin were not linearly correlated reported by Suzuki et al. 16 Regardless the fact that there is no linear relationship between the two factors, the ratio of them might be a valuable variable. The significantly increased VEGF/endostatin ratio in this study might reflect an imbalance between angiogenic inducer and inhibitor.
Results of studies on prognostic value of VEGF and endostatin were not consistent. 21e24 This study did not find the value of endostatin in the prognostic significance, although a systematic review with meta-analysis concluded that endostatin was correlated with the prognosis of NSCLC. 25 In the current study lower VEGF level was found in the patients who lived for more than 5 years compared with the level of those who lived for less than 5 years. But in univariate analysis, the difference did not reach the statistical significance. A meta-analysis reported by Hu et al. demonstrated that high VEGF level was associated with poor outcome in inoperable stage instead of in operable stage. 26 As the inconsistent reports about the correlation of VEGF and endostatin with the prognosis, we assume that it might be not enough to assess only the angiogenic inducers or the inhibitors. In the internal environment, the homeostasis is essential for the normal function and structure. 27 So it is necessary to study the balance of the angiogenic factors.
In the present study, the ratio of VEGF/endostatin was significantly higher in operable NSCLC cases than in the normal control. And it correlated with the prognosis of operable NSCLC. In subgroup analysis, patients with N0 presented significantly different prognosis when the ratio was divided by the median. To date, although there are limitations and controversies about the TNM staging, 28 it still acts as the best common method for measuring the prognosis to NSCLC. The present study suggests that the VEGF/endostatin ratio is an independent factor correlated with the prognosis of NSCLC patients and the ratio might supplement the limitation of the TNM staging.
To date, two categories of medication are used in the development of anti-angiogenic therapy, involving the inhibition of angiogenic factors (bevacizumab and ramucirumab act through this pathway 29 ) and the application of endogenous angiogenesis inhibitors (endostatin is one of the approved therapy in China 30 ). Restoration of proand anti-angiogenic balance in tumors may "normalize" tumor vasculature. 31 Patients perhaps should be treated with different types of anti-angiogenic drugs according to the need of the internal balance of angiogenesis, such as reducing the angiogenic inducers or increasing the angiogenic inhibitors, should not be treated with anti-VEGF or endogenous angiogenic inhibitors without careful selections.
Conclusions
This investigation revealed that an imbalance between VEGF and endostatin levels exits in the serum of operable NSCLC patients. This imbalance predicted the prognosis of NSCLC patients. However, whether the ratio of VEGF/endostatin can be a predictor for some treatments or progression/recurrence of the disease should be further explored in the future. The more we understand the angiogenesis in NSCLC, the more effective modalities would be applied to NSCLC patients.
